The role of prolactin/vasoinhibins in cardiovascular diseases
Abstract Prolactin (PRL) is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary. There are two main isoforms of PRL: 23‐kDa PRL (named full‐length PRL) and vasoinhibins (including 5.6–18 kDa fragments). Both act as circulating hormones and cytokines...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Animal Models and Experimental Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ame2.12264 |
| _version_ | 1797833357900382208 |
|---|---|
| author | Hui Zhao Sugang Gong Yongcong Shi Cijun Luo Hongling Qiu Jing He Yuanyuan Sun Yuxia Huang Shang Wang Yuqing Miao Wenhui Wu |
| author_facet | Hui Zhao Sugang Gong Yongcong Shi Cijun Luo Hongling Qiu Jing He Yuanyuan Sun Yuxia Huang Shang Wang Yuqing Miao Wenhui Wu |
| author_sort | Hui Zhao |
| collection | DOAJ |
| description | Abstract Prolactin (PRL) is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary. There are two main isoforms of PRL: 23‐kDa PRL (named full‐length PRL) and vasoinhibins (including 5.6–18 kDa fragments). Both act as circulating hormones and cytokines to stimulate or inhibit vascular formation at different stages and neovascularization, including endothelial cell proliferation and migration, protease production, and apoptosis. However, their effects on vascular function and cardiovascular diseases are different or even contrary. In addition to the structure, secretion regulation, and signal transduction of PRL/vasoinhibins, this review focuses on the pathological mechanism and clinical significance of PRL/vasoinhibins in cardiovascular diseases. |
| first_indexed | 2024-04-09T14:21:52Z |
| format | Article |
| id | doaj.art-85769a460b34477790501b1c141ea78c |
| institution | Directory Open Access Journal |
| issn | 2576-2095 |
| language | English |
| last_indexed | 2024-04-09T14:21:52Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Animal Models and Experimental Medicine |
| spelling | doaj.art-85769a460b34477790501b1c141ea78c2023-05-04T16:07:59ZengWileyAnimal Models and Experimental Medicine2576-20952023-04-0162819110.1002/ame2.12264The role of prolactin/vasoinhibins in cardiovascular diseasesHui Zhao0Sugang Gong1Yongcong Shi2Cijun Luo3Hongling Qiu4Jing He5Yuanyuan Sun6Yuxia Huang7Shang Wang8Yuqing Miao9Wenhui Wu10School of Materials and Chemistry & Institute of Bismuth and Rhenium University of Shanghai for Science and Technology Shanghai ChinaDepartment of Cardio‐Pulmonary Circulation, School of Medicine Shanghai Pulmonary Hospital, Tongji University Shanghai ChinaRespiratory Medicine Dongchuan District People's Hospital Kunming ChinaDepartment of Cardio‐Pulmonary Circulation, School of Medicine Shanghai Pulmonary Hospital, Tongji University Shanghai ChinaDepartment of Cardio‐Pulmonary Circulation, School of Medicine Shanghai Pulmonary Hospital, Tongji University Shanghai ChinaDepartment of Cardio‐Pulmonary Circulation, School of Medicine Shanghai Pulmonary Hospital, Tongji University Shanghai ChinaDepartment of Cardio‐Pulmonary Circulation, School of Medicine Shanghai Pulmonary Hospital, Tongji University Shanghai ChinaDepartment of Cardio‐Pulmonary Circulation, School of Medicine Shanghai Pulmonary Hospital, Tongji University Shanghai ChinaDepartment of Cardio‐Pulmonary Circulation, School of Medicine Shanghai Pulmonary Hospital, Tongji University Shanghai ChinaSchool of Materials and Chemistry & Institute of Bismuth and Rhenium University of Shanghai for Science and Technology Shanghai ChinaDepartment of Cardio‐Pulmonary Circulation, School of Medicine Shanghai Pulmonary Hospital, Tongji University Shanghai ChinaAbstract Prolactin (PRL) is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary. There are two main isoforms of PRL: 23‐kDa PRL (named full‐length PRL) and vasoinhibins (including 5.6–18 kDa fragments). Both act as circulating hormones and cytokines to stimulate or inhibit vascular formation at different stages and neovascularization, including endothelial cell proliferation and migration, protease production, and apoptosis. However, their effects on vascular function and cardiovascular diseases are different or even contrary. In addition to the structure, secretion regulation, and signal transduction of PRL/vasoinhibins, this review focuses on the pathological mechanism and clinical significance of PRL/vasoinhibins in cardiovascular diseases.https://doi.org/10.1002/ame2.12264cardiovascular diseasesendothelial cellsprolactinvasoinhibins |
| spellingShingle | Hui Zhao Sugang Gong Yongcong Shi Cijun Luo Hongling Qiu Jing He Yuanyuan Sun Yuxia Huang Shang Wang Yuqing Miao Wenhui Wu The role of prolactin/vasoinhibins in cardiovascular diseases Animal Models and Experimental Medicine cardiovascular diseases endothelial cells prolactin vasoinhibins |
| title | The role of prolactin/vasoinhibins in cardiovascular diseases |
| title_full | The role of prolactin/vasoinhibins in cardiovascular diseases |
| title_fullStr | The role of prolactin/vasoinhibins in cardiovascular diseases |
| title_full_unstemmed | The role of prolactin/vasoinhibins in cardiovascular diseases |
| title_short | The role of prolactin/vasoinhibins in cardiovascular diseases |
| title_sort | role of prolactin vasoinhibins in cardiovascular diseases |
| topic | cardiovascular diseases endothelial cells prolactin vasoinhibins |
| url | https://doi.org/10.1002/ame2.12264 |
| work_keys_str_mv | AT huizhao theroleofprolactinvasoinhibinsincardiovasculardiseases AT suganggong theroleofprolactinvasoinhibinsincardiovasculardiseases AT yongcongshi theroleofprolactinvasoinhibinsincardiovasculardiseases AT cijunluo theroleofprolactinvasoinhibinsincardiovasculardiseases AT honglingqiu theroleofprolactinvasoinhibinsincardiovasculardiseases AT jinghe theroleofprolactinvasoinhibinsincardiovasculardiseases AT yuanyuansun theroleofprolactinvasoinhibinsincardiovasculardiseases AT yuxiahuang theroleofprolactinvasoinhibinsincardiovasculardiseases AT shangwang theroleofprolactinvasoinhibinsincardiovasculardiseases AT yuqingmiao theroleofprolactinvasoinhibinsincardiovasculardiseases AT wenhuiwu theroleofprolactinvasoinhibinsincardiovasculardiseases AT huizhao roleofprolactinvasoinhibinsincardiovasculardiseases AT suganggong roleofprolactinvasoinhibinsincardiovasculardiseases AT yongcongshi roleofprolactinvasoinhibinsincardiovasculardiseases AT cijunluo roleofprolactinvasoinhibinsincardiovasculardiseases AT honglingqiu roleofprolactinvasoinhibinsincardiovasculardiseases AT jinghe roleofprolactinvasoinhibinsincardiovasculardiseases AT yuanyuansun roleofprolactinvasoinhibinsincardiovasculardiseases AT yuxiahuang roleofprolactinvasoinhibinsincardiovasculardiseases AT shangwang roleofprolactinvasoinhibinsincardiovasculardiseases AT yuqingmiao roleofprolactinvasoinhibinsincardiovasculardiseases AT wenhuiwu roleofprolactinvasoinhibinsincardiovasculardiseases |